<DOC>
	<DOCNO>NCT02305602</DOCNO>
	<brief_summary>This Phase I , open label , study investigate effect VentriGel injection patient experience first , large ST elevation myocardial infarction ( STEMI ) treat PCI within past 3 year evidence leave ventricular remodeling .</brief_summary>
	<brief_title>A Study VentriGel Early Late Post-myocardial Infarction Patients</brief_title>
	<detailed_description>Evaluate safety feasibility VentriGel deliver trans-endocardially subject leave ventricular ejection fraction ( LVEF ) 25 45 % secondary MI . Secondary endpoint look efficacy variable ESV , EDV , EF , scar mass .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<criteria>1 . The subject 3075 year age 2 . The subject must able provide inform consent 3 . At least 60 day 3 year pass since prior acute myocardial infarction ( AMI ) time VentriGel administration 4 . The AMI must meet following criterion : 1 . First time diagnosis myocardial infarction AND ; 2 . Meet STEMI criterion American College Cardiology ( ACC ) /American Heart Association ( AHA ) ( e.g . ST elevation least 2 lead &gt; 0.2 mV V1 , V2 V3 &gt; 0.1mV lead least two anterior lead ) , new leave bundle branch block ( LBBB ) 5 . Evidence leave ventricular remodel secondary myocardial infarction use 2D echocardiography cMR ; 1. LVEF must ≥ 25 % ≤ 45 % AND ; 2 . The left ventricular wall thickness ≥ 8 mm target area . 6 . Successful percutaneous coronary intervention ( PCI ) restore TIMI II high flow infarcted area 7 . Negative pregnancy test [ serum human chorionic gonadotropin ( βhCG ) ] woman childbearing potential within 24 hour prior dose ) less 2 year postmenopausal agree use adequate contraception study . 8 . Must ambulatory , willing able comply protocol , include followup visit 9 . Subject must receive best medical treatment postMI clinical presentation accord American College Cardiology ( ACC ) /American Heart Association ( AHA ) guideline 10 . For subject indicated heart failure medical therapy , subject must stable therapy include betablockers angiotensin convert enzyme inhibitor , tolerate , least 45 day prior therapy delivery 1 . Contraindications cardiac MR 2 . NYHA Functional Classification 4 heart failure within prior 6 month . 3 . Significant coronary artery stenosis may require percutaneous surgical revascularization within six month enrollment , determine principal investigator 4 . Left ventricular thrombus , leave ventricular aneurysm , subject postinfarction pericarditis , subject wall motion abnormality outside region infarct relate artery 5 . Frequent , recurrent , sustain ( &gt; 30 second ) ventricular tachycardia 30 day prior VentriGel administration 6 . ECG 24 hour Holter Monitor follow finding : Bifascicular block ( leave bundle branch block right bundle branch block plus left hemiblock ) Higher grade AV block ( i.e . 3rd degree ) Ventricular tachycardia ( &gt; = 3 beat VT ) 7 . Atrial fibrillation heart rate great 110 bpm . 8 . Severe valvular disease ( e.g . aortic stenosis worse moderate severity , valvular insufficiency require surgical repair ) history heart valve replacement . 9 . Known allergy porcine proteins prior implantation porcine derive medical product include cardiac valve ECM product . 10 . Etiology heart failure due cause ( e.g . hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericardial disease , amyloidosis , active myocarditis ) index MI . 11 . Severe peripheral vascular disease impair femoral arterial access . 12 . Less 3 year , cancer free , since end treatment cancer ( exception basal cell carcinoma ) 13 . Alcohol drug dependency within six month prior enrollment 14 . Cerebrovascular event within 90 day prior major surgical procedure major trauma within 14 day prior enrollment 15 . Participation , define receive test article , experimental clinical study within 30 day prior administration VentriGel ( i.e . screen failure study exclude subject ) 16 . Uncontrolled hypertension define systolic blood pressure ( SBP ) &gt; 180 mmHg and/or diastolic blood pressure ( DBP ) &gt; 110 mmHg 17 . Abnormal laboratory value define performed screening : Aspartate aminotransferase [ AST ] / alanine aminotransferase [ ALT ] ≥ 3 time upper limit normal ( ULN ) Serum creatinine ≥ 2.0 mg/dL Platelet count &lt; 50,000/mm3 Hemoglobin &lt; 9.0 g/dL HbA1c &gt; 9.0 % PT aPTT clinically significant elevation relative local laboratory norm 18 . Any cardiac noncardiac condition illness , opinion principal investigator , may place subject undue risk compromise objective study . 19 . Institutional interpretation cMR EF data outside ≥ 25 % ≤ 45 % limit</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>extracellular matrix</keyword>
</DOC>